Price Graph
Price
Yield
These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|---|---|---|
Dr. Love currently serves on the board of directors of Royalty Pharma plc and Structure Therapeutics Inc. | |||
Dr. Horning previously served on the board of directors of Foundation Medicine, Inc. from 2015 to 2018 and EQRx, Inc. from 2021 to 2023. | |||
Kelly A. Kramer, 57 Retired Chief Financial Officer, Cisco Systems | |||
Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell therapies to treat serious autoimmune and inflammatory diseases. | |||
Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout 12 countries. | |||
Dr. Barton is the John G. Kirkwood and Arthur A. Noyes Professor of Chemistry Emerita in the Division of Chemistry and Chemical Engineering at the California Institute of Technology, where she was a member of the faculty for more than 30 years and served as the Norman Davidson Leadership Chair of the division from 2009 to 2019. | |||
Harish Manwani, 71 Senior Operating Partner, Blackstone; Retired Chief Operating Officer, Unilever | |||
Daniel P. O’Day Chairman of the Board Our Board believes that it is currently in the best interests of Gilead and its stockholders for Mr. O’Day to serve as our Chief Executive Officer and Chairman of the Board because it positions Mr. O’Day to effectively drive future strategy and decision-making for our organization. In addition to public, private and non-profit board experience, Mr. O’Day has a track record of success in highly scientific and competitive therapeutic areas, deep understanding of the evolving healthcare environment around the world and unwavering commitment to driving innovation across all aspects of the business. As the individual with primary responsibility and accountability for managing our day-to-day operations, Mr. O’Day can provide unified leadership of Gilead and help to make sure that key business and strategic issues, risks and opportunities are brought to our Board’s attention in a way that prioritizes and makes the best use of our Board’s time. |
|
Name and Principal
Position |
Year | Salary | Bonus |
Stock
Awards |
Option
Awards |
Non-Equity
Incentive Plan Compensation |
All Other
Compensation |
Total | ||||||||||||||||||||||
|
Daniel P. O’Day
Chairman and Chief Executive Officer |
2024 | $ | 1,771,201 | $ | — | $ | 12,426,816 | $ | 4,125,011 | $ | 4,028,096 | $ | 1,338,268 | $ | 23,689,392 | |||||||||||||||
| 2023 | $ | 1,740,962 | $ | — | $ | 11,865,090 | $ | 3,749,966 | $ | 4,036,200 | $ | 1,215,472 | $ | 22,607,690 | ||||||||||||||||
| 2022 | $ | 1,691,154 | $ | — | $ | 10,603,901 | $ | 3,750,014 | $ | 4,716,480 | $ | 859,704 | $ | 21,621,253 | ||||||||||||||||
|
Andrew D. Dickinson
Chief Financial Officer |
2024 | $ | 1,083,969 | $ | — | $ | 4,080,024 | $ | 1,300,029 | $ | 1,608,840 | $ | 36,896 | $ | 8,109,758 | |||||||||||||||
| 2023 | $ | 1,052,396 | $ | — | $ | 4,143,271 | $ | 1,299,966 | $ | 1,574,304 | $ | 37,886 | $ | 8,107,823 | ||||||||||||||||
| 2022 | $ | 1,018,419 | $ | — | $ | 3,992,603 | $ | 1,474,983 | $ | 1,885,572 | $ | 31,121 | $ | 8,402,698 | ||||||||||||||||
|
Johanna Mercier
Chief Commercial Officer |
2024 | $ | 1,148,038 | $ | — | $ | 4,139,594 | $ | 1,300,029 | $ | 1,845,246 | $ | 176,158 | $ | 8,609,065 | |||||||||||||||
| 2023 | $ | 1,114,035 | $ | — | $ | 4,190,733 | $ | 1,299,966 | $ | 1,805,440 | $ | 176,580 | $ | 8,586,754 | ||||||||||||||||
| 2022 | $ | 1,081,471 | $ | — | $ | 4,301,757 | $ | 1,612,496 | $ | 1,995,732 | $ | 244,997 | $ | 9,236,453 | ||||||||||||||||
|
Merdad V. Parsey,
M.D., Ph.D. Chief Medical Officer |
2024 | $ | 1,141,486 | $ | — | $ | 4,206,347 | $ | 1,325,004 | $ | 1,410,810 | $ | 27,484 | $ | 8,111,131 | |||||||||||||||
| 2023 | $ | 1,108,215 | $ | — | $ | 4,269,768 | $ | 1,324,984 | $ | 1,657,632 | $ | 26,248 | $ | 8,386,847 | ||||||||||||||||
| 2022 | $ | 1,072,800 | $ | — | $ | 4,350,004 | $ | 1,612,496 | $ | 1,986,552 | $ | 15,362 | $ | 9,037,214 | ||||||||||||||||
|
Deborah H. Telman
Executive Vice President, Corporate Affairs and General Counsel |
2024 | $ | 967,723 | $ | — | $ | 2,151,425 | $ | 812,500 | $ | 1,436,148 | $ | 704,083 | $ | 6,071,879 | |||||||||||||||
| 2023 | $ | 936,865 | $ | — | $ | 1,895,703 | $ | 812,512 | $ | 1,288,980 | $ | 337,168 | $ | 5,271,228 | ||||||||||||||||
| 2022 | $ | 380,769 | $ | 1,200,000 | $ | 1,999,890 | $ | 499,979 | $ | 536,548 | $ | 205,763 | $ | 4,822,949 | ||||||||||||||||
No Customers Found
Suppliers
| Supplier name | Ticker |
|---|---|
| salesforce.com, inc. | CRM |
| Oracle Corporation | ORCL |
| Pitney Bowes Inc. | PBI |
| Microsoft Corporation | MSFT |
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|---|---|---|
| GILEAD SCIENCES, INC. | - | 2,209,470 | 0 |
| O'Day Daniel Patrick | - | 468,689 | 0 |
| O'Day Daniel Patrick | - | 383,685 | 0 |
| Dickinson Andrew D | - | 165,674 | 0 |
| Mercier Johanna | - | 121,152 | 0 |
| Dickinson Andrew D | - | 106,534 | 0 |
| Parsey Merdad | - | 100,189 | 0 |
| Parsey Merdad | - | 70,130 | 0 |
| Mercier Johanna | - | 48,326 | 0 |
| Patterson Sandra | - | 37,078 | 0 |
| Telman Deborah H | - | 36,918 | 0 |
| Wilfong Diane E. | - | 30,711 | 0 |
| Patterson Sandra | - | 29,754 | 0 |
| BARTON JACQUELINE K | - | 26,056 | 0 |
| Bluestone Jeffrey | - | 8,920 | 0 |
| WELTERS ANTHONY | - | 7,922 | 0 |
| Telman Deborah H | - | 6,762 | 0 |
| LOVE TED W | - | 512 | 0 |
| Lofton Kevin E | - | 0 | 90,766 |